

[Sebia, Inc.](#)

written by CAP TODAY
June 22, 2025

Sebia is a global leader in specialized in vitro diagnostics, providing instruments and reagents for screening and monitoring diseases in Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathies, Autoimmune and Infectious diseases, and other rare disorders.



©2026 CAP TODAY, all rights reserved.

[Polymedco, LLC](#)

written by CAP TODAY
June 22, 2025

Polymedco's mission is to save lives through early detection of life-threatening diseases like colorectal cancer and cardiac diseases by partnering with healthcare systems, payors, providers, and reference labs to build effective screening and early detection programs.



©2026 CAP TODAY, all rights reserved.

[HORIBA](#)

written by CAP TODAY
June 22, 2025

Meet HORIBA in Chicago at the 2025 ADLM, Booth #328. HORIBA designs, develops and distributes worldwide, in vitro diagnostic systems mainly destined for biological analysis in medical laboratories.



©2026 CAP TODAY, all rights reserved.

[HemoSonics](#)

written by CAP TODAY
June 22, 2025

HemoSonics' Quantra® Hemostasis System is revolutionizing bleeding management with its next-generation whole-blood viscoelastic analyzer.



©2026 CAP TODAY, all rights reserved.

[EpreDia](#)

written by CAP TODAY
June 22, 2025

EpreDia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific,

[ARKRAY](#)

written by CAP TODAY
June 22, 2025

ARKRAY has a long-standing history with fully automated urine chemistry and sediment analysis. Hundreds of urinalysis systems are placed throughout the USA. The new ARKRAY AUTION Bridge (AUTION Eye AI-4510 + AUTION Max AX-4060) is a fully automated, walk

[ARK Diagnostics, Inc](#)

written by CAP TODAY
June 22, 2025

ARK Diagnostics, Inc. is committed to improving health care through the design, development, manufacture and distribution of in vitro diagnostic (IVD) immunoassays for therapeutic drug monitoring (TDM), urine drug testing (UDT) and other small molecules. Our focus is the production of high quality, convenient, cost-effective products for routine use in research and clinical practice.

Spectrum of anti-PF4 disorders widens

written by CAP TODAY

June 22, 2025

June 2025—For a relatively sleepy field of study, heparin-induced thrombocytopenia has produced more than its share of thrills in the past few years. HIT (sometimes called HITT, with the extra “T” denoting thrombosis) gave way to urgent discussions about vaccine-induced immune thrombotic thrombocytopenia, or VITT, at one particularly panicky point in the COVID-19 pandemic. Take another spin of the wheel: “VITT-like” is now primarily used to refer to cases in which patients have received neither heparin nor a vaccine. Even more recently, researchers have identified a new syndrome, referred to as monoclonal gammopathy of thrombotic significance (MGTS). Publications have put this disorder into three groups. “I think this is going to be the biggest thing in the thrombophilia field in a long time,” predicts Anand Padmanabhan, MD, PhD, professor, Mayo Clinic. Unlike HIT and VITT, MGTS is a chronic condition. “It may end up being part of a thrombophilia profile in the coming years.”



At ADLM, sessions on race, equity, and litigation

written by CAP TODAY

June 22, 2025

June 2025—The Duffy null phenotype, legal matters, and unmet needs in STI testing are three of the topics on offer at the ADLM meeting next month in Chicago.

Breast HER2 FISH groups 2 and 4: study of excision specimens

written by CAP TODAY
June 22, 2025

June 2025—The authors of a recently published study suggest repeating HER2 testing on the excision specimen for the small number of breast cancer biopsies with group two and group four FISH results. The aim of their study was to determine if FISH group two and group four cases change HER2 status after repeated testing on additional specimens.